Stay updated on Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page
- Check6 days agoChange DetectedAdded a Locations section listing Pennsylvania as the study site and removed the old Pennsylvania Locations entry. Updated page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page revision label updated from v3.3.1 to v3.3.2. The previous revision label v3.3.1 is removed.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision: v3.3.1 was added and revision: v3.2.0 was removed from the page, representing a minor metadata update. No visible changes to core content, study details, or functionality were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedThe government funding lapse notice about updates and NIH operation status was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check56 days agoChange DetectedMinor cosmetic adjustments to page layout and formatting were observed, with no changes to core trial content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check85 days agoChange DetectedImportant updates include a notice about potential funding-related outages and current operating status, plus a version bump to v3.2.0. If this is a public-facing page, the new operating status information is the key change.SummaryDifference4%

Stay in the know with updates to Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.